1[1]Greco FA, Hainsworth JD. Tumors of unknown origin[J]. CA,1992,42:96.
2[2]Sporn JR,Greenberg BR. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site[J]. Semin Oncol,1993,20:261.
3[3]Treat J, Falchuk SG, Tremblay C, et al. PhaseⅡtrial of methotrexate-FAM in adenocarcinoma of unknown primary[J]. Eur J Cancer Clin Oncol,1989,25:1053.
4[4]Hainsworth JD,Wright EP,Gray GF Jr,et al. Poorly differentiated carcinoma of unknown primary site:correlation of light microscopic findings with response to cisplatin-based combination chemotherapy[J]. J Clin Oncol, 1987,5:1272.
5[5]Weir L,Keane T,Cummings B,et al. Radiation treatment of cervical lymph node metastasis from an unknown primary:an analysis of outcome by treatment volume and other prognostic factors[J].Radiother Oncol,1995,35:206.
6[6]Carlson LS,Fletcher GH,Oswald MJ. Guidelines for the radiotherapeutic techniques for cervical metastases from an unknown primary[J]. Int J Radiat Oncol Biol Phys,1986,12:2101.
3Hirohisa Katagiri,Mitsuru Takahashi,Jiro Inagaki,et al. Determining the site of the primary cancer in patient with skeletat metastasis of unknown origin[J]. Cancer,1999,86(3):533-537.
4Mevio E, Gorini E, Sbrocca M, et al. The role of positron e- mission tomography (PET) in the management of cervical lymph nodes metastases from an unknown primary turnout. Acta Otorhinolaryngol Ital, 2004, 24(6): 342-347.
5Pavlidis N,Fizazi K. Cancer of unknown primary(CUP). Crit Rev Oncol Heraatol, 2005,54 (3) : 243-250.
6Van de Wouw AJ ,Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours: incidence and population-based survival of 1285 patients in Southeast Neth- erlands,1984-1992. Eur J Cancer,2002,38(3) :409-413.
7Shaw PHS,Adams R,Jordan C,et al. A clinical review of the investigation and management of carcinoma of unknown pri- mary in asingle cancer network. Clin Oncol, 2007,19 ( 1 ) : 87- 95.
8Vant-Veer LJ,Weigelt B. Road map to metastasis. Nat Med, 2003,9 (8) : 999-1000.
9Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards,options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer, 2003,89 Suppl 1 : $59-$66.
10Greco FA, Burris HA, Erland EB, et al. Carcinoma of un- known primary site. Long term follow-up after treatment with paclitaxe| earboplatin and etoposide. Cancer, 2000, 89 26552660.